I wanted to share an analysis I've conducted on Sanofi over the past five years using both comparable methods and a 2-Stage DCF approach. According to my findings, the market value appears to be at least 22% undervalued in comparison with its fair value. Moreover, considering the post-COVID effects on pharmaceutical companies, I believe Sanofi presents a...
after analyzing 2021 financial reports of SPH with Pitroscki and compare it's performance with last years performance and considering the weekly consolidation and good volume rise if consolidation box is broken by a candle this can be a potential entry point, after entry trade should be manage using Darvas box
